Physician profile
Christopher Jay Ehly
NPI 1346318417
$6,305.70
in general payments reported to CMS, 2019-2025
41 companies · $632 in 2025
The $632 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,013 · 2021: $1,027 · 2022: $522 · 2023: $884 · 2024: $650 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.74 | 2019-2025 | |
| Lilly USA, LLC | $857.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $842.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $403.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $398.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.94 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $240.71 | 2019-2024 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.44 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $166.25 | 2019-2021 | |
| Organogenesis INC. | $155.43 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $148.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.76 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $109.14 | 2019-2023 | Spravato |
| Esperion Therapeutics, INC. | $104.90 | 2024-2025 | Nexletol |
| Allergan, INC. | $102.67 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ehly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.